Seattle Genetics has been a pioneer in cancer treatment ever since it came on the market. Recently, the biotech giant announced that it was offering public stock in an effort to raise money to fund further drug research and development. Seattle Genetics set the initial offering at $480 million dollars. The company, headquartered in Bothell, decided to increase the public offering to $522 million dollars. Clay Siegall, CEO, decided to increase the amount due to the enormous outcry and interest from prospective investors. The new funds will focus on research and development as well as growth for the company. This growth takes the form of infrastructure and hiring new employees. Funds will also be used to expand the use of the drug Adcetris. This
